BRIEF published on 03/24/2026 at 07:35, 4 months 9 days ago Sanofi Releases Q1 2026 Aide-Mémoire to Support Financial Analysis Innovation Biopharma Sanofi Financial Modeling Q1 2026 Results
BRIEF published on 03/24/2026 at 07:35, 4 months 9 days ago Mise en ligne du guide financier Q1 2026 de Sanofi Investisseurs Résultats Trimestriels Sanofi Document Financier Q1 2026
BRIEF published on 03/24/2026 at 07:35, 4 months 9 days ago Sanofi publie un aide-mémoire du premier trimestre 2026 pour soutenir l'analyse financière Innovation Biopharma Sanofi Modélisation Financière Résultats Du T1 2026
BRIEF published on 03/24/2026 at 07:35, 4 months 9 days ago Sanofi's Q1 2026 financial guide is now online Investors Quarterly Results Sanofi Financial Document Q1 2026
PRESS RELEASE published on 03/24/2026 at 07:30, 4 months 9 days ago Press release: Availability of the Q1 2026 aide-mémoire Sanofi announces availability of Q1 2026 aide-mémoire for financial modelling purposes. Details on non-comparable items, currency impact, and share count included. Results to be published on April 23, 2026 Sanofi Results Aide-mémoire Financial Modelling Q1 2026
PRESS RELEASE published on 03/24/2026 at 07:30, 4 months 9 days ago Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire » Mise en ligne du document 'Q1 2026 aide-mémoire' par Sanofi pour faciliter la modélisation financière des résultats trimestriels avec des déclarations prospectives Déclarations Prospectives Sanofi Modélisation Financière Aide-mémoire Q1 2026
BRIEF published on 03/18/2026 at 07:05, 4 months 15 days ago Sanofi : Désignation de thérapie innovante pour le venglustat aux États-Unis FDA Sanofi Venglustat Maladie De Gaucher Découverte Médicale
BRIEF published on 03/18/2026 at 07:05, 4 months 15 days ago Sanofi's Venglustat Earns Breakthrough Therapy Designation for Gaucher Disease Type 3 FDA Sanofi Breakthrough Therapy Venglustat Gaucher Disease
BRIEF published on 03/18/2026 at 07:05, 4 months 15 days ago Le venglustat de Sanofi obtient la désignation de thérapie innovante pour la maladie de Gaucher de type 3 FDA Sanofi Thérapie Révolutionnaire Venglustat Maladie De Gaucher
BRIEF published on 03/18/2026 at 07:05, 4 months 15 days ago Sanofi: Breakthrough Therapy Designation for venglustat in the United States FDA Sanofi Venglustat Medical Discovery Gaucher's Disease
Published on 08/01/2026 at 01:58, 2 days 2 hours ago Clôture de l'option sur la propriété de graphite au Québec
Published on 08/01/2026 at 01:20, 2 days 3 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 3 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 4 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/03/2026 at 04:05, 46 minutes ago UD info Launches One-Stop Industrial-Grade SD and microSD Card Solutions
Published on 08/03/2026 at 03:30, 1 hour 21 minutes ago Coway Releases 21st Sustainability Report for FY2025
Published on 08/03/2026 at 00:05, 4 hours 46 minutes ago Publication of the result of the voluntary public tender offer for all Addiko shares
Published on 08/02/2026 at 08:15, 20 hours 36 minutes ago Holcim signs agreement to divest its business in the Philippines
Published on 08/01/2026 at 16:35, 1 day 12 hours ago HIZENERGY Enters Global Top Tier with BloombergNEF Tier 1 Listing
Published on 07/31/2026 at 21:00, 2 days 7 hours ago Carrefour finalise la vente de sa participation minoritaire dans CarrefourSA en Turquie à Yeni Mağazacılık A.Ş., société opérant l'enseigne de A101 et contrôlée par le Groupe Aydın
Published on 07/31/2026 at 21:00, 2 days 7 hours ago Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:27, 2 days 9 hours ago Engagements de conservation d’actions (Pacte Dutreil)
